



(43) International Publication Date

13 April 2017 (13.04.2017)

## (51) International Patent Classification:

*G01N 33/68* (2006.01) *A61K 31/138* (2006.01)  
*A61P 25/24* (2006.01) *A61K 31/343* (2006.01)  
*A61K 31/135* (2006.01)

(71) Applicant: **THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.** [US/US]; 6720-A Rockledge Drive, Suite 100, Bethesda, Maryland 20817 (US).

## (21) International Application Number:

PCT/US2016/055675

(72) Inventors: **POLLARD, Harvey B.**; 11008 Lamplighter Lane, Potomac, Maryland 20854 (US). **DALGARD, Clifton L.**; 3302 Winnett Rd., Chevy Chase, Maryland 20815 (US).

## (22) International Filing Date:

6 October 2016 (06.10.2016)

(74) Agents: **BUCK, Todd B.** et al.; 1111 Pennsylvania Ave NW, Washington, District of Columbia 20004 (US).

## (25) Filing Language:

English

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,

## (26) Publication Language:

English




## (30) Priority Data:

62/239,004 8 October 2015 (08.10.2015)







US

*[Continued on next page]*

## (54) Title: BIOMARKERS FOR DIAGNOSING POST TRAUMATIC STRESS DISORDER

**FIG. 1A****FIG. 1B****FIG. 1C**

(57) Abstract: The invention relates to methods of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD).

**FIG. 1D****FIG. 1E****FIG. 1F****FIG. 1G****FIG. 1H****FIG. 1I**



DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

## BIOMARKERS FOR DIAGNOSING POST TRAUMATIC STRESS DISORDER

### Statement Regarding Federally Sponsored Research or Development

**[0001]** Part of the work performed during development of this invention utilized U.S. Government funds through grant number CDMRP-PTSD (PTO74415). The U.S. Government has certain rights in this invention.

### Reference to Sequence Listing

**[0002]** A computer readable text file, entitled "044508-5052-P1-SequenceListing.txt," created on or about October 8, 2015 with a file size of about 8.7 kb contains the sequence listing for this application and is hereby incorporated by reference in its entirety.

### Background of the Invention

#### *Field of the Invention*

**[0003]** The invention relates to methods of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD).

#### *Background of the Invention*

**[0004]** Post-traumatic stress disorder (PTSD) is a psychiatric disease, which occurs following exposure to traumatic events. PTSD may be acute or chronic, and can have a waxing and waning course of symptoms that can persist for months, years or decades [2,3]. Patients with chronic PTSD have changes in their immune systems which have been interpreted as due to sustained activation of the hypothalamic-pituitary-adrenal (HPA) axis, and resultant sympatho-adrenal-medullary (SAM) stress [4-6],[7]. The difference between a chronic PTSD patient and a resilient healthy control is that for a stress experience that resolves normally, the initially high levels of norepinephrine from the adrenal medulla, *via* the SAM, are eventually reduced by transient elevation of cortisol from the HPA. However, some studies have found chronic PTSD patients to have intrinsically low levels of circulating cortisol. Failure of feedback inhibition has been conjectured to be a driver for excessive levels of cell-mediated and proinflammatory cytokine expression [8-10]. For example, cytokines such as TNF-alpha and IL-6 are known to cross the blood brain barrier and to regulate the immune response through stimulation of the HPA axis [10,11]. Consistently, it has been reported that IL-1-beta [12], TNF-alpha [13], and IL-6 [14,15] are elevated in the serum of PTSD patients. Furthermore, in the cerebrospinal fluid (CSF) of PTSD patients, both IL-6 [16] and norepinephrine [17] are reported

to be higher in PTSD patients than in normal controls. The transition from a conventional high cortisol state to a low cortisol/high norepinephrine state has also been documented in a cohort of pediatric PTSD patients [16].

**[0005]** Patients with a diagnosis of PTSD often have co-morbid conditions such as major depressive disorder (MDD), as well as addiction to alcohol and other drugs [6,19]. Interestingly, while PTSD patients who are co-morbid with MDD have higher levels of serum IL-6 [20], those PTSD patients without co-morbid MDD have serum IL-6 levels that are identical to normal controls [20]. Furthermore, in a carefully controlled study of CSF from the NIMH cohort of civilian chronic PTSD patients, all with smaller dorsal hippocampus and relatively free from MDD, concentrations of Corticotrophin Releasing Factor (CRF), IL-6, BDNF, IGF-1 and Substance P were identical to levels in CSF from normal controls [1]. These results seem to suggest that cytokines or chemokines may not be involved in PTSD.

## Summary of the Invention

**[0006]** The invention relates to methods of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD), with the methods comprising determining the ratio of monocyte chemoattractant protein 4 (MCP-4) to monocyte chemoattractant protein 1 (MCP-1) and comparing the MCP-4/MCP-1 ratio (MMR) to a normal MMR. An elevation in the MMR over normal ratios is indicative that the subject has an increased risk of suffering from PTSD.

**[0007]** The invention relates to methods of monitoring the progression of post-traumatic stress disorder (PTSD) in a subject, with the methods comprising determining the MMR in the subject on at least two different days and comparing the MMRs over time to determine if the subject's MMR is changing over time. An increase in the subject's MMR over time is indicative that the PTSD is progressing in the subject.

**[0008]** The invention relates to methods of diagnosing post-traumatic stress disorder (PTSD) in a subject, with the methods comprising determining the MMR in the subject and comparing the MMR to a normal MMR. An elevation in the MMR over a normal ratio is indicative that the subject has or is suffering from PTSD.

**[0009]** The invention also relates to methods of diagnosing PTSD in a male subject, with the methods comprising determining levels of at least one marker selected from the group consisting of monocyte chemoattractant protein 1 (MCP-1) and thymus and activation-regulated chemokine (TARC) in at least one sample obtained from the male subject, and comparing the MCP-1 or TARC

levels in the at least one sample to normal MCP-1 or TARC levels to determine if the male subject's MCP-1 or TARC levels are altered compared to the normal MCP-1 or TARC levels. A change in the male subject's MCP-1 or TARC levels indicative that the male subject has an increased risk of suffering from PTSD.

**[0010]** The invention also relates to methods of diagnosing PTSD in a female subject, with the methods comprising determining levels of at least one marker selected from the group consisting of monocyte chemoattractant protein 4 (MCP-4) and monocyte interacting protein 1 $\beta$  (MIP-1 $\beta$ ) in at least one sample obtained from the female subject, and comparing the MCP-4 or MIP-1 $\beta$  levels in the at least one sample to normal MCP-4 or MIP-1 $\beta$  levels to determine if the female subject's MCP-4 or MIP-1 $\beta$  levels are altered compared to the normal MCP-4 or MIP-1 $\beta$  levels. A change in the female subject's MCP-4 or MIP-1 $\beta$  levels indicative that the female subject has an increased risk of suffering from PTSD.

### **Brief Description of the Drawings**

**[0011]** FIGURE 1 (A-I) depicts dot-plot distributions of MCP-4, MCP-1 and the MCP-4/MCP-1 ratio in PTSD and healthy control plasma at 2 AM (a) and 9 AM (b), and in CSF at 9 AM (c). (a,b,c). MCP-1(Monocyte Chemoattractant Protein-1, CCL2) is lower in PTSD plasma. (d,e,f). MCP-4 (Monocyte Chemoattractant Protein-4, CCL13) is higher in PTSD plasma. Levels of MCP-4 are vanishingly low in the CSF and cannot be accurately measured. (g,h,i). MCP-4/MCP-1 ratio is elevated in the 2 AM PTSD plasma (about 20%, p = 0.02) and in 9 AM PTSD plasma (about 66%, p = 0.004). All p values are two-tailed. Dotted horizontal lines are lower limits of detection (LLOD).

**[0012]** FIGURE 2 (A-D) depicts the influence of PTSD on the circadian rhythms for the MCP-4/MCP-1 ratio, and individually for MCP-4 and MCP-1. (a). Circadian rhythm for the MCP-4/MCP-1 ratio in PTSD patients and healthy controls. The dotted contours are +/- 2 standard deviations of the data at each time point. (b). Circadian rhythm data for the MCP-4/MCP-1 ratio in which the data have been normalized, patient by patient, and filtered for high frequency variation. (c). Circadian rhythm data for MCP-4 alone, in which the data have been normalized, patient by patient, and filtered for high frequency variation. (d). Circadian rhythm data for MCP-1 alone, in which the data have been normalized, patient by patient, and filtered for high frequency variation. PTSD seems to affect both the phase and the amplitude of the MCP-4/MCP-1 ratio, as well as its component analytes.

**[0013]** FIGURE 3 depicts the tracking of MCP-4 and MCP-1 in healthy controls and PTSD patients. (a) healthy controls; (b) PTSD patients.

**[0014]** FIGURE 4 (A-B) depicts the plasma concentrations of MCP-4 and MCP-1 in PTSD patients and healthy controls. (a) absolute concentrations; (b) average concentrations

**[0015]** FIGURE 5 (A-D) depicts area under the curve (AUC) for receiver operator curves (ROCs) for embodiments of the present invention.

**[0016]** FIGURE 6 depicts the AUC for ROCs for various chemokines.

**[0017]** FIGURE 7 (A-H) depicts circadian dependence of plasma chemokines in PTSD and controls.

**[0018]** FIGURE 8 (A-D) depicts the distribution of MCP-4/MCP-1 ratio in plasma over a circadian interval for patients with PTSD and healthy controls.

**[0019]** FIGURE 9 (A-D) depicts the distribution of MIP-1 $\beta$  in plasma over a circadian interval for patients with PTSD and healthy controls.

**[0020]** FIGURE 10 (A-D) depicts the distribution of TARC in plasma over a circadian interval for patients with PTSD and healthy controls.

### **Detailed Description of the Invention**

**[0021]** The invention relates to methods of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD), with the methods comprising determining the ratio of monocyte chemoattractant protein 4 (MCP-4) to monocyte chemoattractant protein 1 (MCP-1) and comparing the MCP-4/MCP-1 ratio (MMR) a normal MMR. An elevation in the MMR over normal ratios is indicative that the subject has an increased risk of suffering from PTSD.

**[0022]** Both MCP-4(CCL13) and MCP-1(CCL2) share 67% sequence homology and function as molecular attractants (“chemokines”) for monocytes, and, to a lesser extent, for lymphocytes and basophils. Both chemokines also share CCR2 as a common receptor [29,30]. Segman et al (2005) [31] studied peripheral blood mononuclear cells (PBMNs) in survivors of terror attacks in Israel. Yehuda et al (2009) [32] studied whole blood expression patterns in survivors of the World Trade Center attack in New York. Neylan et al (2011) [33] studied purified CD14+ monocytes, from men and women with PTSD, and other co-morbidities. In all three cases, a common observation was suppression of gene expression. The timing of blood collection was not mentioned or suggested in these publications.

**[0023]** The ratio of two monocyte chemokines, MCP-4 (CCL13) and MCP-1 (CCL2), constitute a time-independent, bivariate plasma biomarker for PTSD. Furthermore, in plasma from PTSD patients

there is a disordered circadian pattern that is superimposed on the quantitatively elevated MCP-4/MCP-1 ratio, and its component individual analytes. These results suggest that the biomarker comprising the MCP-4/MCP-1 ratio is independent of an additional defect in circadian biology which may also characterize PTSD patients.

**[0024]** Recent studies, however, indicate that circulating monocytes exhibit a circadian oscillation, coinciding with endogenous MCP-1 expression that is driven by an autonomous circadian clock, and for which the time-dependent variation is independent of infection or metabolic stress [34,35]. In humans, nocturnal peak blood levels, encompassing the time period between 1 AM and 3 AM, can be observed for circulating monocytes, T lymphocytes and B lymphocytes [36]. Nocturnal monocytes activate the expression of MCP-1 [34]. Beginning at about 4 AM, levels of circulating monocytes, B cells and T cells begin to decline [36]. Coincidentally, monocyte expression of MCP-1 is blocked by the transcription factors CLOCK, BMAL1 and EZH2 [34]. MCP-1 plasma levels of healthy controls also significantly drop from 2 AM to 9 AM by about 70% ( $p = 0.001$ ) (Table 1 below and Figure 1). In the case of PTSD patients, MCP-1 levels also drop, but by a greater proportion, about 90%, and with greater significance ( $p = 2 \times 10^{-6}$ ). This process is also seen in greater detail in the circadian pattern. It is therefore possible that this disease-specific difference is the dynamic basis for MCP-1 contributing to the lower denominator portion of the PTSD-specific MCP-4/MCP-1 biomarker.

Table 1

Analyte	Healthy Controls				PTSD patients			
	Ratio (CSF/plasma)	p-value	%R>2	%R<0.5	Ratio (CSF/plasma)	p-value	%R>2	%R<0.5
GM-CSF	~LLOD	n.a.	n.a.	n.a.	~LLOD	n.a.	n.a.	n.a.
IFN- $\gamma$	$\uparrow 1.3 \pm 0.4$	0.406	44%	22%	$\approx 0.9 \pm 0.4$	0.890	25%	13%
IL-10	~LLOD	n.a.	n.a.	n.a.	~LLOD	n.a.	n.a.	n.a.
IL-12 p70	~LLOD	0.857	50%	40%	~LLOD	0.703	20%	40%
IL-1 $\beta$	~LLOD	n.a.	n.a.	n.a.	~LLOD	n.a.	n.a.	n.a.
IL-2	$\uparrow 2.4 \pm 0.6$	0.0000	56%	0%	$\uparrow 2.0 \pm 0.8$	0.098	44%	22%
IL-6	$\uparrow 1.6 \pm 0.5$	0.211	38%	13%	$\uparrow 1.8 \pm 0.4$	0.028	45%	0%
IL-8	$\uparrow 20.4 \pm 5.5$	0.0000	100%	0%	$\uparrow 17.7 \pm 4.6$	0.0000	100%	0%
TNF- $\alpha$	~LLOD	n.a.	n.a.	n.a.	~LLOD	n.a.	n.a.	n.a.
Eotaxin-1	~LLOD	n.a.	n.a.	n.a.	~LLOD	n.a.	n.a.	n.a.
Eotaxin-3	$\approx 1.1 \pm 0.1$	0.649	0%	0%	$\approx 0.9 \pm 0.1$	0.397	0%	9%
IP-10	$\uparrow 3.6 \pm 1.1$	0.001	90%	10%	$\uparrow 2.6 \pm 1.0$	0.028	73%	9%
MCP-1	$\uparrow 9.0 \pm 1.3$	0.0000	100%	0%	$\uparrow 9.5 \pm 1.3$	0.0000	100%	0%
MCP-4	~LLOD	n.a.	n.a.	n.a.	~LLOD	n.a.	n.a.	n.a.
MDC	$\downarrow 18.6 \pm 5.6$	0.0000	0%	100%	$\downarrow 11.6 \pm 3.1$	0.0000	0%	100%
MIP-1 $\beta$	$\uparrow 5.1 \pm 1.0$	0.0000	90%	0%	$\uparrow 3.8 \pm 0.9$	0.0000	82%	0%
TARC	$\downarrow 10.1 \pm 8.6$	0.0000	0%	67%	$\downarrow 4.7 \pm 2.6$	0.0000	11%	67%
plasma MCP-1 vs CSF IL-6	$\uparrow 7.5 \pm 1.9$	0.0000	100%	0%	$\uparrow 11.1 \pm 3.9$	0.0000	100%	0%

$\uparrow$  PTSD>HC;  $\downarrow$  PTSD<HC

~LLOD: (viz, the analyte was too low in either the 2 AM or 9 AM plasma or 9 AM CSF to calculate accurately. n.a.: not available

**[0025]** Less is known about the genetics or possible circadian variation of plasma MCP-4. MCP-4 plasma levels, however, also significantly decrease from 2 AM to 9 AM, by about 60% in Healthy Controls ( $P = 0.004$ ), compared to a significant decrease of only about 40% in PTSD patients ( $p = 0.01$ ). This process is also seen in greater detail in the circadian pattern (see Figure 2c). Thus the PTSD patients appear to express relatively reduced amounts of both MCP-1 and MCP-4 as the wake period begins, with a greater reduction in MCP-1 than for MCP-4. Thus the elevation of the MCP-4/MCP-1 ratio in PTSD patients may be due to PTSD-dependent modifications in synthesis rates of both of these analytes.

**[0026]** Sleep disturbance is a hallmark feature of PTSD [21,22]. It is therefore possible that sleep deprivation might be the root cause of the disordered circadian profile for MCP-4 and MCP-1. In a comprehensive study of ten fully instrumented normal males, however, Born et al (1997) [36] reported that following a 24 hour sleep deprivation experience, the succeeding 24 hours were characterized only by a blunting of the circadian changes in immune cell numbers, including monocytes, as well as in TNF $\alpha$ , IL-1 $\beta$ , and IL-6 levels. Born et al also reported that there were no changes in phase or appearance of multimodality. Thus the circadianopathy observed for PTSD patients for plasma MCP-4 and MCP-1 appears to be disease-specific. Furthermore, because there

were no observed PTSD-specific variations at the one available time point in any of the cytokines and chemokines in the CSF, the data disclosed herein may argue for a PTSD contribution to specific deficits in monocyte or immune cell biology. This conclusion is consistent with results mentioned above for PBMC [31] and whole blood [32], respectively, and for CD14+ mononuclear cells [33].

**[0027]** The central clock mechanism in the brain is run by light exposure and activation of CLOCK/BMAL1 signaling in the suprachiasmatic nucleus [37]. Subsidiary clocks in the periphery take their cue from this central mechanism, *via* the hypothalamic-Pituitary-Adrenal (HPA) axis, and adapt the exact subsidiary timing to their own requirements. In healthy controls, the circadian clock program is intrinsically plastic and can reversibly changed in response to alterations in, for example, metabolism or sunrise time[28]. By contrast, chronic neuropsychiatric disorders have been associated with conditions in which the central clock appears to permanently “lose track of time” [38]. In the case of PTSD, however, these patients exhibit phase-shifted peripheral clocks for MCP-1 and MCP-4 and, at least in the case of MCP-4, a different pattern altogether.

**[0028]** For example, Figure 2c shows that MCP-4 levels in healthy controls have a monomodal distribution over 24 hours. In contrast MCP-4 distribution in PTSD patients transitions to four discrete peaks over 24 hours. In the case of MCP-1, Figure 2d shows MCP-1 in healthy controls also distributes in a monomodel distribution, peaking in the late night hours and lagging MCP-4 by about 2 hours (see Figure 3). MCP-1 in PTSD patients, however, lags the major late night peak by about 6 hours, and appears to “catch up” somewhat to lower levels in the late afternoon and evening.

**[0029]** Data presented here show that few PTSD-specific changes in CSF can be detected from simply screening cytokines and chemokines at 9 AM. In fact, the only detectable change was a small reduction in IL-8. These data are consistent with data reported by Bonne et al (2011) for a subset of cytokines in the same CSF samples.

**[0030]** In the meantime, there are other concentration gradients between 9 AM CSF and plasma. The highest elevation in the gradients was for IL-8 (elevated about 14-fold); for MCP-1 (elevated about 7-fold); for IP-10 (elevated about 7-fold); for MIP-1 $\beta$  and for Eotaxin 3 (both elevated about 4-fold). The most reduced analytes were MCP-4 (reduced about 80-100-fold); Eotaxin 1 (reduced about 18-fold); MDC (reduced about 25-fold); TARC (reduced about 9-fold); and TNF $\alpha$  (reduced about 6-fold).

**[0031]** Based on the data herein, the MCP-4/MCP-1 ratio constitutes a quantitative candidate biomarker for PTSD, which has the benefit of being measurable at any hour blood can be drawn. Furthermore, the circadian pattern of expression for both the ratio, and its individual components,

MCP-4 and MCP-1, are phase-shifted and multimodal compared to healthy controls. Thus, the relative MCP-4 and MCP-1 levels in plasma, accessed through the MCP-4/MCP-1 ratio, can be used as a functional biomarker for PTSD. Moreover, these data suggest that the MCP-4/MCP-1 ratio is independent of any defect in circadian biology which could also affect PTSD patients.

**[0032]** In addition, the circadian rhythms for plasma MCP-4 and MCP-1 are disordered in PTSD patients. Thus it cannot be ruled out that circadian dysfunction, possibly involving monocytes, or immune cells in general, may play an important role in the behavioral problems afflicting this class of psychiatric patients.

**[0033]** The invention also relates to methods of diagnosing PTSD in a male subject, with the methods comprising determining levels of at least one marker selected from the group consisting of monocyte chemoattractant protein 1 (MCP-1) and thymus and activation-regulated chemokine (TARC) in at least one sample obtained from the male subject, and comparing the MCP-1 or TARC levels in the at least one sample to normal MCP-1 or TARC levels to determine if the male subject's MCP-1 or TARC levels are altered compared to the normal MCP-1 or TARC levels. A change in the male subject's MCP-1 or TARC levels indicative that the male subject has an increased risk of suffering from PTSD.

**[0034]** MCP-1 or CCL2, UniProt Accession No. P13500, is a well-known C-C motif chemokine and is tethered to endothelial cells via proteoglycans. MCP-1 is a protein of 99 amino acids, with residues 1-23 being the signal sequence. MCP-1 typically binds to the CCR2 and CCR4 receptors. As used herein, the term MCP-1 is not limited to a specific amino acid sequence but instead is used to mean a chemokine found in the blood of a subject that would be readily characterized as MCP-1 in any standard or commercially available analysis, *e.g.*, ELISA assay. Thus any proteins detected as MCP-1, *e.g.*, ability to bind to an antibody raised against a known MCP-1 protein, would be considered MCP-1 for the purposes of the present invention. In some embodiments, the term MCP-1 means the mature (full length polypeptide without the signal sequence) form of the MCP-1 protein.

**[0035]** In specific embodiments, the term MCP-1 means a protein with an amino acid sequence at least about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:1. In other embodiments, the term MCP-1 means a protein with an amino acid sequence at least about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:2.

MKVSAALLCL LLIAATFIPQ GLAQPDAINA PVTCCYNFTN RKISVQRLAS YRRITSSKCP  
KEAVIFKTIV AKEICADPKQ KWVQDSMDHL DKQTQTPKT (SEQ ID NO: 1)

QPDAINAPVT CCYNFTNRKI SVQRLASYRR ITSSKCPKEA VIFKTIVAKE ICADPKQKVV  
QDSMDHLDKQ TQTPKT (SEQ ID NO: 2)

**[0036]** Thymus and activation-regulated chemokine (TARC or CCL17), UniProt Accession No. Q92583, is a well-known C-C motif chemokine that is generally expressed in the thymus and, to lesser extent, in the lungs, colon and small intestine. TARC is a protein of 94 amino acids, with residues 1-23 constituting the signal sequence. It generally acts as a chemotactic factor for T cells and may also participate in T cell development as well as trafficking of mature T cells. TARC typically binds to the CCR4 receptor. As used herein, the term TARC is not limited to a specific amino acid sequence but instead is used to mean a chemokine found in the blood of a subject that would be readily characterized as TARC in any standard or commercially available analysis, *e.g.*, ELISA assay. For example, TARC has at least two naturally occurring variants at amino acid positions 5 and 67 of the full length peptide chain. Both variants, however, are detected as TARC in ELISA assays, thus both variants would be considered as TARC for the purposes of the present invention. Any proteins detected as TARC, *e.g.*, ability to bind to an antibody raised against a known TARC protein, would be considered TARC for the purposes of the present invention. In some embodiments, the term TARC means the mature (full length polypeptide without the signal sequence) form of the TARC protein.

**[0037]** In specific embodiments, the term TARC means a protein with an amino acid sequence at least about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:3. In other embodiments, the term TARC means a protein with an amino acid sequence at least about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:4.

MAPLKMLALV TLLGASLQH IHAARGTNVG RECCLEYFKG AIPLRKLKTW YQTSEDCSRD  
AIVFVTVQGR AICSDPNNKR VKNAVKYLQS LERS (SEQ ID NO: 3)

ARGTNVGREC CLEYFKGAIP LRKLKTWYQT SEDCSRDAIV FVTVQGRAIC SDPNNKRVKN  
AVKYLQSLER S (SEQ ID NO: 4)

**[0038]** The invention also relates to methods of diagnosing PTSD in a female subject, with the methods comprising determining levels of at least one marker selected from the group consisting of monocyte chemoattractant protein 4 (MCP-4) and monocyte interacting protein 1 $\beta$  (MIP-1 $\beta$ ) in at

least one sample obtained from the female subject, and comparing the MCP-4 or MIP-1 $\beta$  levels in the at least one sample to normal MCP-4 or MIP-1 $\beta$  levels to determine if the female subject's MCP-4 or MIP-1 $\beta$  levels are altered compared to the normal MCP-4 or MIP-1 $\beta$  levels. A change in the female subject's MCP-4 or MIP-1 $\beta$  levels indicative that the female subject has an increased risk of suffering from PTSD.

**[0039]** Monocyte interacting protein 1 $\beta$  (MIP-1 $\beta$ ) is a chemokine that is generated from the CCL4 C-C motif chemokine. Specifically, the CCL4 chemokine is a protein of 92 amino acids, with residues 1-23 being the signal sequence. The "mature" CCL4 protein is thus a protein of 69 residues with the amino acid sequence of residues 24-92 of the full length CCL4. MIP-1 $\beta$  is further processed to a slightly short chain constituting residues 3-69 of the mature CCL4 protein (residues 26-92 of the full length CCL4). As used herein, MIP-1 $\beta$  can include the full length and mature forms of CCL4, as well as the short form of CCL4. In specific embodiments, the term MIP-1 $\beta$  means only the mature CCL4 chain and the shorter CCL4 chain (residues 3-69 of the mature CCL4) version of the protein. In other specific embodiments, the term MIP-1 $\beta$  means only the short chain (residues 3-69 of the mature CCL4) version of the protein.

**[0040]** In specific embodiments, the term MIP-1 $\beta$  means a protein with an amino acid sequence at least about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:5 (full length). In other embodiments, the term MIP-1 $\beta$  means a protein with an amino acid sequence at least about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:6 (mature CCL4). In other embodiments, the term MIP-1 $\beta$  means a protein with an amino acid sequence at least about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:7 (MIP-1 $\beta$ ).

MKLCVTVLSL LMLVAAFCSP ALSAPMGS DP PTACCF SYTA RKLPRNFVVD YYETSSLCSQ  
PAVVFQTKRS KQVCADPSES WVQEYVYDLE LN (SEQ ID NO:5)

APMGSDPPTA CCFSYTARKL PRNFVVDYYE TSSLCSQPAV VFQTKRSKQV CADPSES WVQ  
EYVYDLELN (SEQ ID NO:6)

MGSDPPTACC FSYTARKLPR NFVVDYYETS SLCSQPAVVF QTKRSKQVCA DPSES WVQ  
EYDLELN (SEQ ID NO:7)

**[0041]** MCP-4 or CCL 13, UniProt Accession No. Q99616, is a well-known C-C motif chemokine and is widely expressed in small intestine, thymus, colon, lung, trachea, stomach, lymph nodes and pulmonary artery smooth muscle cells. MCP-4 is a protein of 98 amino acids, with residues 1-16 being the signal sequence. The mature or “long chain” MCP-4 protein (full length protein without the signal sequence) can be further processed or cleaved into two additional chains, known as medium and short chains, which are shown below. MCP-4 typically binds to the CCR2B and CCR3 receptors and is a chemotactic factor that attracts monocytes, lymphocytes, basophils and eosinophils. As used herein, the term MCP-4 is not limited to a specific amino acid sequence but instead is used to mean a chemokine found in the blood of a subject that would be readily characterized as MCP-4 in any standard or commercially available analysis, *e.g.*, ELISA assay. Thus any proteins detected as MCP-4, *e.g.*, ability to bind to an antibody raised against a known MCP-4 protein, would be considered MCP-4 for the purposes of the present invention. In specific embodiments, the term MCP-4 means only the mature MCP-4 chain, the medium MCP-4 chain version and the shorter MCP-4 chain version of the protein. In other specific embodiments, the term MCP-4 means only the medium MCP-4 chain version and the shorter MCP-4 chain version of the protein. In additional embodiments, the term MCP-4 means only the shorter MCP-4 chain version of the protein.

**[0042]** In specific embodiments, the term MCP-4 means a protein with an amino acid sequence at least about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:8 (full length). In other embodiments, the term MCP-4 means a protein with an amino acid sequence at least about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:9 (long chain MCP-4). In other embodiments, the term MCP-4 means a protein with an amino acid sequence at least about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:10 (medium chain MCP-4). In other embodiments, the term MCP-4 means a protein with an amino acid sequence at least about 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO:11 (short chain MCP-4).

MKVSAVLLCL LLMTAAFNPQ GLAQPDALNV PSTCCFTFSS KKISLQRLKS YVITTSRCPQ  
KAVIFRTKLG KEICADPKEK WVQNYMKHLG RKAHTLKT (SEQ ID NO:8)

FNPQGLAQPD ALNPSTCCF TFSSKKISLQ RLKSYVITTS RCPQKAVIFR TKLGKEICAD  
PKEKWWQNYM KHLGRKAHTL KT (SEQ ID NO:9)

LAQPDALNVP STCCFTFSSK KISLQRLKSY VITTSRCPQK AVIFRTKLGK EICADPKEKW  
VQNYMKHLGR KAHLKT (SEQ ID NO:10)

QPDALNPST CCFTFSSKKI SLQRLKSYVI TTSRCPQKAV IFRTKLGKEI CADPKEKWQ  
NYMKHLGRKA HTLKT (SEQ ID NO:11)

**[0043]** A polypeptide having an amino acid sequence at least, for example, about 95% “identical” to a reference an amino acid sequence, e.g., SEQ ID NO:2, is understood to mean that the amino acid sequence of the polypeptide is identical to the reference sequence except that the amino acid sequence may include up to about five modifications per each 100 amino acids of the reference amino acid sequence. In other words, to obtain a peptide having an amino acid sequence at least about 95% identical to a reference amino acid sequence, up to about 5% of the amino acid residues of the reference sequence may be deleted or substituted with another amino acid or a number of amino acids up to about 5% of the total amino acids in the reference sequence may be inserted into the reference sequence. These modifications of the reference sequence may occur at the N-terminus or C-terminus positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among amino acids in the reference sequence or in one or more contiguous groups within the reference sequence.

**[0044]** As used herein, “identity” is a measure of the identity of nucleotide sequences or amino acid sequences compared to a reference nucleotide or amino acid sequence. In general, the sequences are aligned so that the highest order match is obtained. “Identity” per se has an art-recognized meaning and can be calculated using published techniques. (See, e.g., Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York (1988); Biocomputing: Informatics And Genome Projects, Smith, D. W., ed., Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey (1994); von Heinje, G., Sequence Analysis In Molecular Biology, Academic Press (1987); and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York (1991)). While there are several methods to measure identity between two polynucleotide or polypeptide sequences, the term “identity” is well known to skilled artisans (Carillo, H. & Lipton, D., Siam J Applied Math 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego (1994) and Carillo, H. & Lipton, D., Siam J Applied Math 48:1073 (1988). Computer programs may also contain methods and algorithms that calculate identity and similarity. Examples of computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., Nucleic Acids

Research 12(i):387 (1984)), BLASTP, ExPASy, BLASTN, FASTA (Atschul, S. F., et al., J Molec Biol 215:403 (1990)) and FASTDB. Examples of methods to determine identity and similarity are discussed in Michaels, G. and Garian, R., Current Protocols in Protein Science, Vol 1, John Wiley & Sons, Inc. (2000), which is incorporated by reference.

**[0045]** In one embodiment of the present invention, the algorithm used to determine identity between two or more polypeptides is BLASTP. In another embodiment of the present invention, the algorithm used to determine identity between two or more polypeptides is FASTDB, which is based upon the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990), incorporated by reference). In a FASTDB sequence alignment, the query and reference sequences are amino sequences. The result of sequence alignment is in percent identity. In one embodiment, parameters that may be used in a FASTDB alignment of amino acid sequences to calculate percent identity include, but are not limited to: Matrix=PAM, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject amino sequence, whichever is shorter.

**[0046]** If the reference sequence is shorter or longer than the query sequence because of N-terminus or C-terminus additions or deletions, but not because of internal additions or deletions, a manual correction can be made, because the FASTDB program does not account for N-terminus and C-terminus truncations or additions of the reference sequence when calculating percent identity. For query sequences truncated at the N- or C- termini, relative to the reference sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C- terminus to the reference sequence that are not matched/aligned, as a percent of the total bases of the query sequence. The results of the FASTDB sequence alignment determine matching/alignment. The alignment percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score can be used for the purposes of determining how alignments “correspond” to each other, as well as percentage identity. Residues of the reference sequence that extend past the N- or C-termini of the query sequence may be considered for the purposes of manually adjusting the percent identity score. That is, residues that are not matched/aligned with the N- or C-termini of the comparison sequence may be counted when manually adjusting the percent identity score or alignment numbering.

**[0047]** For example, a 90 amino acid residue query sequence is aligned with a 100 residue reference sequence to determine percent identity. The deletion occurs at the N-terminus of the query sequence and therefore, the FASTDB alignment does not show a match/alignment of the first 10

residues at the N-terminus. The 10 unpaired residues represent 10% of the reference sequence (number of residues at the N- and C-termini not matched/total number of residues in the reference sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched (100% alignment) the final percent identity would be 90% (100% alignment – 10% unmatched overhang). In another example, a 90 residue query sequence is compared with a 100 reference sequence, except that the deletions are internal deletions. In this case the percent identity calculated by FASTDB is not manually corrected, since there are no residues at the N- or C-termini of the subject sequence that are not matched/aligned with the query. In still another example, a 110 amino acid query sequence is aligned with a 100 residue reference sequence to determine percent identity. The addition in the query occurs at the N-terminus of the query sequence and therefore, the FASTDB alignment may not show a match/alignment of the first 10 residues at the N-terminus. If the remaining 100 amino acid residues of the query sequence have 95% identity to the entire length of the reference sequence, the N-terminal addition of the query would be ignored and the percent identity of the query to the reference sequence would be 95%.

**[0048]** As used herein, the terms “correspond(s) to” and “corresponding to,” as they relate to sequence alignment, are intended to mean enumerated positions within the reference protein, e.g., wild-type MCP-1, and those positions in a mutant or related MCP-1 that align with the positions on the reference protein. Thus, when the amino acid sequence of a subject peptide is aligned with the amino acid sequence of a reference MCP-1, e.g., SEQ ID NO:2, the amino acids in the subject sequence that “correspond to” certain enumerated positions of the reference sequence are those that align with these positions of the reference sequence, e.g., SEQ ID NO:2, but are not necessarily in these exact numerical positions of the reference sequence. Methods for aligning sequences for determining corresponding amino acids between sequences are described herein. Accordingly, embodiments of the present invention comprise detecting or determining levels (or ratios thereof) of biomarkers, with the biomarkers corresponding to MCP-1, MCP-4, TARC and/or MIP-1 $\beta$ .

**[0049]** As used herein, the term subject or “test subject” indicates a mammal, in particular a human or non-human primate. The test subject may or may not be in need of an assessment of a predisposition to PTSD. For example, the test subject may or may not have a recollection of an experience that could be associated with PTSD prior to applying the methods of the present invention. In another embodiment, the test subject has not been identified as a subject that may have had an experienced that could lead to PTSD prior to applying the methods of the present invention.

**[0050]** As used herein, PTSD is used as it is commonly understood in the art. In select embodiments, PTSD in the subject is assessed using the Structured Clinical Interview for DSM-IV (SCID) as is understood in the art. As is also understood in the art, the severity of PTSD can range from mild to severe. In select embodiments of the present invention, the severity of the PTSD can be assessed at any time, i.e., before or after determining the MMR in the subject. The severity of the PTSD can be assessed in any manner, such as, but not limited to, the Clinician-Administered PTSD scale (CAPS).

**[0051]** As used herein, the term means “increased risk” is used to mean that the test subject has an increased chance of developing or acquiring PTSD compared to a normal individual. The increased risk may be relative or absolute and may be expressed qualitatively or quantitatively. For example, an increased risk may be expressed as simply determining the subject’s MMR, TARC levels and/or MIP-1 $\beta$  levels and placing the patient in an “increased risk” category, based upon previous population studies. Alternatively, a numerical expression of the subject’s increased risk may be determined based upon the MMR, TARC levels and/or MIP-1 $\beta$  levels, respectively. As used herein, examples of expressions of an increased risk include but are not limited to, odds, probability, odds ratio, p-values, attributable risk, relative frequency, positive predictive value, negative predictive value, and relative risk.

**[0052]** For example, the correlation between a subject’s MMR, TARC levels and/or MIP-1 $\beta$  levels and the likelihood of suffering from PTSD may be measured by an odds ratio (OR) and by the relative risk (RR). If  $P(R^+)$  is the probability of developing PTSD for individuals with the risk profile (R) and  $P(R^-)$  is the probability of developing PTSD for individuals without the risk profile, then the relative risk is the ratio of the two probabilities:  $RR = P(R^+)/P(R^-)$ .

**[0053]** In case-control studies, however, direct measures of the relative risk often cannot be obtained because of sampling design. The odds ratio allows for an approximation of the relative risk for low-incidence diseases and can be calculated:  $OR = (F^+/(1-F^+))/(F^-/(1-F^-))$ , where  $F^+$  is the frequency of a risk profile in cases studies and  $F^-$  is the frequency of risk profile in controls.  $F^+$  and  $F^-$  can be calculated using the MMR frequencies of the study.

**[0054]** The attributable risk (AR) can also be used to express an increased risk. The AR describes the proportion of individuals in a population exhibiting PTSD due to a specific member of the MMR or TARC levels and/or MIP-1 $\beta$  levels. AR may also be important in quantifying the role of individual components (specific member, e.g., MCP-4 or MCP-1) in condition etiology and in terms of the public health impact of the individual marker. The public health relevance of the AR

measurement lies in estimating the proportion of cases of PTSD in the population that could be prevented if the MMR, TARC levels and/or MIP-1 $\beta$  levels or individual component were considered normal. AR may be determined as follows:  $AR = P_E(RR-1)/(P_E(RR-1)+1)$ , where AR is the risk attributable to an MMR, TARC levels and/or MIP-1 $\beta$  levels, and  $P_E$  is the frequency of exposure to an MMR, TARC levels and/or MIP-1 $\beta$  levels within the population at large. RR is the relative risk, which can be approximated with the odds ratio when the MMR, TARC levels and/or MIP-1 $\beta$  levels under study has a relatively low incidence in the general population.

**[0055]** In one embodiment, the increased risk of a patient can be determined from p-values that are derived from association studies. Specifically, associations with specific MMRs, TARC levels and/or MIP-1 $\beta$  levels can be performed using regression analysis by regressing the MMR, TARC levels and/or MIP-1 $\beta$  levels with PTSD. In addition, the regression may or may not be corrected or adjusted for one or more factors. The factors for which the analyses may be adjusted include, but are not limited to age, sex, weight, ethnicity, geographic location, fasting state, state of pregnancy or post-pregnancy, menstrual cycle, general health of the subject, alcohol or drug consumption, caffeine or nicotine intake and circadian rhythms, and the subject's genotype to name a few.

**[0056]** Increased risk can also be determined from p-values that are derived using logistic regression. Binomial (or binary) logistic regression is a form of regression which is used when the dependent is a dichotomy and the independents are of any type. Logistic regression can be used to predict a dependent variable on the basis of continuous and/or categorical independents and to determine the percent of variance in the dependent variable explained by the independents; to rank the relative importance of independents; to assess interaction effects; and to understand the impact of covariate control variables. Logistic regression applies maximum likelihood estimation after transforming the dependent into a "logit" variable (the natural log of the odds of the dependent occurring or not). In this way, logistic regression estimates the probability of a certain event occurring. These analyses are conducted with the program SAS.

**[0057]** Techniques to assay levels of individual components of the MMR, TARC levels and/or MIP-1 $\beta$  levels from test samples are well known to the skilled technician, and the invention is not limited by the means by which the components are assessed. In one embodiment, levels of the individual components of the MMR, TARC levels and/or MIP-1 $\beta$  levels are assessed using mass spectrometry in conjunction with ultra-performance liquid chromatography (UPLC), high-performance liquid chromatography (HPLC), and UPLC to name a few. Other methods of assessing levels of the individual components include biological methods, such as but not limited to ELISA assays

**[0058]** The assessment of the levels of the individual components of the MMR, TARC levels and/or MIP-1 $\beta$  levels can be expressed as absolute or relative values and may or may not be expressed in relation to another component, a standard an internal standard or another molecule of compound known to be in the sample. If the levels are assessed as relative to a standard or internal standard, the standard may be added to the test sample prior to, during or after sample processing.

**[0059]** The subject's MMR, TARC levels and/or MIP-1 $\beta$  levels is(are) compared to an MMR, TARC levels and/or MIP-1 $\beta$  levels that is(are) deemed to be a normal MMR, TARC levels and/or MIP-1 $\beta$  levels . To establish the MMR, TARC levels and/or MIP-1 $\beta$  levels of a normal individual, an individual or group of individuals may be first assessed for PTSD to establish that the individual or group of individuals is not suffering from PTSD. Once established, the MMR of the individual or group of individuals can then be determined to establish a "normal" MMR, TARC levels and/or MIP-1 $\beta$  levels. In one embodiment, normal MMR, TARC levels and/or MIP-1 $\beta$  levels can be ascertained from the same subject when the subject is deemed to not be suffering from or exhibiting sign (clinical or otherwise) of PTSD. In one embodiment, a "normal" MMR, TARC levels and/or MIP-1 $\beta$  levels is(are) assessed in the same subject from whom the sample is taken prior to the onset of measureable, perceivable or diagnosed PTSD. That is, the term "normal" with respect to MMR, TARC levels and/or MIP-1 $\beta$  levels can be used to mean the subject's baseline MMR, TARC levels and/or MIP-1 $\beta$  levels prior to the onset of PTSD. The MMR, TARC levels and/or MIP-1 $\beta$  levels can then be reassessed periodically and compared to the subject's baseline MMR, TARC levels and/or MIP-1 $\beta$  levels. Thus, the present invention also include methods of monitoring the progression of PTSD in a subject (including monitoring the effectiveness of a treatment of PTSD), with the methods comprising determining the subject's MMR, TARC levels and/or MIP-1 $\beta$  levels more than once over a period of at least more than one day. As used herein, a "day" is a 24-hour time period, not necessarily a different calendar day. For example, some embodiments of the methods of the present invention will comprise determining the subject's MMR, TARC levels and/or MIP-1 $\beta$  levels two, three, four, five, six, seven, eight, nine, 10 or even more times over a period of time, such as a year, two years, three, years, four years, five years, six years, seven years, eight years, nine years or even 10 years or longer. The methods of monitoring a subject's risk of suffering from PTSD would also include embodiments in which the subject's MMR, TARC levels and/or MIP-1 $\beta$  levels is(are) assessed during and after treatment of PTSD. In other words, the present invention also includes methods of monitoring the efficacy of treatment of PTSD by assessing the subject's MMR, TARC levels and/or MIP-1 $\beta$  levels over the course of the treatment and after the treatment. The treatment may be any treatment designed to treat the symptoms or root cause of MMR.

**[0060]** In another embodiment, a normal MMR, TARC levels and/or MIP-1 $\beta$  levels is (are) assessed in a sample from a different subject or patient (from the subject being analyzed) and this different subject does not have or is not suspected of having PTSD. In still another embodiment, the normal MMR, TARC levels and/or MIP-1 $\beta$  levels is(are) assessed in a population of healthy individuals, the constituents of which display no signs of PTSD. Thus, the subject's MMR, TARC levels and/or MIP-1 $\beta$  levels can be compared to normal MMR, TARC levels and/or MIP-1 $\beta$  levels generated from a single normal sample or MMR, TARC levels and/or MIP-1 $\beta$  levels generated from more than one normal sample.

**[0061]** The invention also relates to methods of monitoring the progression of post-traumatic stress disorder (PTSD) in a subject, with the methods comprising determining the MMR, TARC levels and/or MIP-1 $\beta$  levels in the subject on at least two different days and comparing the MMRs, TARC levels and/or MIP-1 $\beta$  levels over time to determine if the subject's MMR, TARC levels and/or MIP-1 $\beta$  levels is(are) changing over time. An increase in the subject's MMR and/or MIP-1 $\beta$  levels over time is indicative that the PTSD is progressing in the subject. A decrease in the subject's TARC levels over time is indicative that the PTSD is progressing in the subject.

**[0062]** The invention also relates to methods of diagnosing post-traumatic stress disorder (PTSD) in a subject, with the methods comprising determining the MMR, TARC levels and/or MIP-1 $\beta$  levels in the subject and comparing the MMR, TARC levels and/or MIP-1 $\beta$  levels to normal MMR, TARC levels and/or MIP-1 $\beta$  levels. An elevation in the MMR and/or MIP-1 $\beta$  levels over a normal MMR and/or MIP-1 $\beta$  levels is indicative that the subject has or is suffering from PTSD. A decrease in TARC levels over normal TARC levels is indicative that the subject has or is suffering from PTSD.

**[0063]** The invention also relates to methods of treating a subject with post-traumatic stress disorder (PTSD), with the methods comprising determining that the subject has PTSD by using the methods of the invention described herein and administering to the subject with PTSD a therapeutic regimen to treat the PTSD. A therapeutic regimen used to treat PTSD includes but is not limited to, cognitive behavioral therapy (CBT), administration of one or more selective serotonin reuptake inhibitors (SSRIs), administration of one or more anti-anxiety medications and administration of one or more anti-insomnia medications. Specifically, the methods of treatment comprise determining the MMR, TARC levels and/or MIP-1 $\beta$  levels in a sample obtained from the subject, and comparing the MMR, TARC levels and/or MIP-1 $\beta$  levels in the sample to a normal MMR, TARC levels and/or MIP-1 $\beta$  levels to determine if the subject's MMR, TARC levels and/or MIP-1 $\beta$  levels is altered compared to the normal MMR, TARC levels and/or MIP-1 $\beta$  levels , where a change in the subject's MMR compared to those defined as having a normal MMR is indicative that the subject is suffering

from PTSD. An elevation in the MMR and/or MIP-1 $\beta$  levels over a normal MMR and/or MIP-1 $\beta$  levels is indicative that the subject has or is suffering from PTSD. A decrease in TARC levels over normal TARC levels is indicative that the subject has or is suffering from PTSD. Subsequent to this determination, the subject is administered a therapeutic regimen for treating PTSD.

**[0064]** In select embodiments, the SSRIs that are administered to the subject suffering from PTSD are selected from the group consisting of citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, sertraline and zimelidine.

**[0065]** The invention also relates to kits that can be used in the methods of the present invention. Specifically, the present invention provides kits for the diagnosis, monitoring and/or treatment of PTSD, with the kits comprising one or more sets of antibodies that are immobilized onto a solid substrate and specifically bind to at least one of MCP-1, MCP-4, TARC and MIP-1 $\beta$ . In specific embodiments, the kits comprise at least two sets of antibodies immobilized onto a solid substrate, with one set of antibodies directed towards MCP-1 and the second set of antibodies being directed towards MCP-4. In specific embodiments, the kits comprise at least four sets of antibodies immobilized onto a solid substrate, with one set of antibodies directed towards MCP-1, the second set of antibodies being directed towards MCP-4, the third set of antibodies directed towards TARC and the fourth set of antibodies being directed towards MIP-1 $\beta$ .

**[0066]** The antibodies that are immobilized onto the substrate may or may not be labeled. For example, the antibodies may be labeled, *e.g.*, bound to a labeled protein, in such a manner that binding of the specific protein may displace the label and the presence of the marker in the sample is marked by the absence of a signal. In addition, the antibodies that are immobilized onto the substrate may be directly or indirectly immobilized onto the surface. Methods for immobilizing proteins, including antibodies, are well-known in the art, and such methods may be used to immobilize a target protein, *e.g.*, TARC, or another antibody onto the surface of the substrate to which the antibody directed to the specific biomarker can then be specifically bound. In this manner, the antibody directed to the specific biomarker is immobilized onto the surface of the substrate for the purposes of the present invention.

**[0067]** The kits of the present invention may or may not include containers for collecting samples from the subject and one or more reagents, *e.g.*, purified target biomarker such as MCP-1, MCP-4, TARC or MIP-1 $\beta$ , for preparing a calibration curve. The kits may or may not include additional reagents such as wash buffers, labeling reagents and reagents that are used to detect the presence (or absence) of the label.

*Examples***[0068]** *Example 1 – Methods and Materials*

**[0069]** Twelve medication-free outpatients with chronic civilian PTSD (median age 30 years old, 8 women/4 men) and eleven non-traumatized, healthy subjects (median age 29.5 years old, 5 women, 5 men) were selected from the original cohort study.

**[0070]** The healthy control subjects were chosen to match PTSD patients as closely as possible with respect to age, sex and BMI. In the subset of PTSD patients studied here, prodromal PTSD traumas were prepubertal in 5 subjects and as adults for 7 subjects. Time elapsed from trauma exposure was  $26 \pm 4$  years in pre-pubertal trauma, and  $10.1 \pm 8.8$  years in adult exposure. Patients were otherwise physically healthy, did not meet criteria for alcohol or substance abuse, or dependence, for at least six months prior to the study and were not receiving psychotropic medication for at least three weeks prior to lumbar puncture and concomitant venipuncture. The required medication-free period for PTSD patients, however, was extended to six weeks for patients previously taking fluoxetine or other SSRI. In addition, four patients (three female and one male) were included who had a history of trauma but without a follow-on history of PTSD. Although these latter patients were not included in the study, the data for these “trauma controls” were not statistically different from the healthy controls.

**[0071]** Psychiatric diagnoses were established using the Structured Clinical Interview for DSM-IV (SCID). The severity of PTSD was determined using the Clinician-Administered PTSD Scale (CAPS). Severity of depressive, anxiety and overall symptoms was assessed using the Inventory of Depressive Symptomatology (IDS), Hamilton Anxiety Rating Scale (HAMA) and Clinical Global Impression-Severity scale (CGI-S), respectively. Individuals with PTSD and controls did not differ with regard to age, gender distribution, race, or body mass index (BMI). The severity of PTSD was moderate, with a CAPS score of  $73.1 \pm 10.3$ . The severity of depression (IDS  $16.4 \pm 8.2$ ), anxiety (HAMA  $13.1 \pm 6.8$ ) and overall symptoms (CGI-S  $4 \pm 1.2$ ) were moderate as well.

**[0072]** Blood samples were collected from PTSD and healthy control patients. For this study, patients were implanted with indwelling intravenous catheters, and blood was collected each hour over a 27-hour period. There were at least two 9 AM time points in the entire plasma collection process, and samples from the second 9 AM time point were chosen for analysis. Care was taken to ensure that blood samples, drawn by hand from the indwelling catheter, were immediately anti-coagulated with sodium citrate, and plasma collected by centrifugation. Care was also taken to

ensure that nighttime sampling was done without disturbing the patient. Following immediate centrifugation, supernatant solutions were split and stored at -80°C.

**[0073]** Lumbar puncture (LP) was performed between 8:00 and 9:00 AM by an experienced physician. A 20-gauge introducer needle was inserted and approximately 15 cc of CSF was withdrawn, centrifuged at 4,000 RPM and frozen in aliquots at -80°C. The LPs were drawn on different days than the plasma collection.

**[0074]** Two multiplexed assays for cytokines and chemokines were used for analysis of patient and control plasma samples on the SECTOR® Imager 6000 instrument (Meso Scale Discovery, Gaithersburg, MD) The first of these assays was the Human ProInflammatory 9 Plex Assay for the measurement of IL-2, IL-8, IL-12p70, IL-1 $\beta$ , GM-CSF, IFN- $\gamma$ , IL-6, IL-10 and TNF- $\alpha$  (MesoScale catalog #K15007C-4). The second of these assays was the Human Chemokine 9 Plex Assay for the measurement of Eotaxin 1, MIP-1 $\beta$ , Eotaxin-3, TARC, IP-10, IL-8, MCP-1 (CCL2), MDC, and MCP-4 (CCL13) (catalog #K15001C-1). The samples were added to plates that were pre-coated with capture antibodies for the specific cytokines. The plates were sealed and shaken at room temperature for two hours. The plates were washed in PBS + 0.05% Tween-20 and detection antibody solution (1 X or 1  $\mu$ g/mL) was then added. The plates were sealed and shaken at room temperature for two hours. The plate was then washed in PBS + 0.05% Tween-20. Read buffer was added at a 2X concentration, and the plate was read on the SECTOR® 6000 Imager.

**[0075]** Data points were characterized on the basis of reproducible technical replicates, low % coefficient of variation (CV < 5%) present within the linear portion of the standard curve and a value above the lower limit of detection (LLOD). The differences between PTSD samples and normal controls were calculated using a 2-tailed t-test and were taken as significant at the p≤ 0.05 level or more than 2 standard deviations from the mean (SD ≥2.0), as appropriate. Values for all analytes from CSF for healthy controls were statistically indistinguishable from data published by others who had also used the industry-standard MesoScale electrochemiluminescence Sector 6000 platform for analysis [23-26]. For analysis of the relative circadian variation, values for individual patients were normalized to their individual 24 hour means, and changes for each patient were calculated as a percentage. The percentages were added for each hour to create composite profiles for PTSD and healthy control patients. Times were standardized to the sunrise time on the day blood sampling began (Z=0, the Zeitgeber). Circadian rhythms were modeled by fitting data to a cosine function.

**[0076]** *Example 2 – Results*

**[0077]** Table 2 below shows measurements of cytokines and chemokines in plasma collected from both PTSD and healthy control patients at the 9 AM time point. MCP-4 was significantly elevated by about 43%. The p value is 0.01 and the area under the curve (“AUC”) is 0.82. In contrast, MCP-1 was reduced by about 20%. The AUC value is also 0.82. The MCP-1 and MCP-4 data thus stratify in opposite directions.

**[0078]** As shown in the last row in Table 2, by dividing these two inversely directional classifiers, the MCP-4/MCP-1 ratio was elevated 84% in PTSD plasma, and provides a highly significant candidate metric for PTSD plasma collected at 9 AM. The difference is significant, based on both a low p value of 0.004 and a high AUC value of 0.84. This PTSD-specific metric has a higher value at 9 AM than 2 AM (see below), indicating that the signal may be diurnal.

Table2

Analyte	PTSD <sup>1</sup>	HC <sup>1</sup>	p-value <sup>2</sup>	Ratio <sup>3</sup>	AUC <sup>4</sup>
GM-CSF	~LLOD	~LLOD	n.a.	n.a.	n.a.
IFN- $\gamma$	~LLOD	~LLOD	n.a.	n.a.	n.a.
IL-10	0.79 $\pm$ 0.24	0.69 $\pm$ 0.32	0.21	$\approx 1.15 \pm 0.60$	0.69
IL-12 p70	~LLOD	~LLOD	n.a.	n.a.	n.a.
IL-1 $\beta$	0.08 $\pm$ 0.02	0.18 $\pm$ 0.04	0.04	$\downarrow 2.12 \pm 0.63$	0.71
IL-2	0.15 $\pm$ 0.04	0.17 $\pm$ 0.05	0.72	$\approx 0.93 \pm 0.38$	0.55
IL-6	0.47 $\pm$ 0.04	0.77 $\pm$ 0.16	0.15	$\downarrow 1.62 \pm 0.33$	0.74
IL-8	1.67 $\pm$ 0.56	1.98 $\pm$ 0.59	0.67	$\approx 0.84 \pm 0.37$	0.52
TNF- $\alpha$	2.57 $\pm$ 0.41	1.57 $\pm$ 0.22	0.03	$\uparrow 1.64 \pm 0.34$	0.76
Eotaxin	503.45 $\pm$ 37.95	496.81 $\pm$ 37.29	0.91	$\approx 1.01 \pm 0.11$	0.52
Eotaxin-3	6.90 $\pm$ 0.55	6.42 $\pm$ 0.38	0.58	$\approx 1.07 \pm 0.10$	0.63
IP-10	226.06 $\pm$ 30.53	149.66 $\pm$ 13.37	0.04	$\uparrow 1.51 \pm 0.24$	0.73
MCP-1	171.11 $\pm$ 17.01	207.10 $\pm$ 17.49	0.14	$\approx 0.83 \pm 0.11$	0.82
MCP-4	298.35 $\pm$ 27.00	208.62 $\pm$ 23.94	0.01	$\uparrow 1.43 \pm 0.20$	0.77
MDC	1850.02 $\pm$ 155.12	1680.80 $\pm$ 167.21	0.40	$\approx 1.10 \pm 0.14$	0.61
MIP-1 $\beta$	65.85 $\pm$ 8.12	55.38 $\pm$ 4.77	0.36	$\approx 1.18 \pm 0.17$	0.66
TARC	85.52 $\pm$ 13.86	67.32 $\pm$ 10.24	0.30	$\uparrow 1.27 \pm 0.28$	0.70
MCP1/MCP4	0.61 $\pm$ 0.06	1.12 $\pm$ 0.18	4E-03	$\downarrow 1.84 \pm 0.33$	0.84
MCP4/MCP1	1.82 $\pm$ 0.19	1.10 $\pm$ 0.16	4E-03	$\uparrow 1.66 \pm 0.28$	0.84

**[0079]** Several other individual cytokines and chemokines were also significantly different in the PTSD 9 AM plasmas compared to healthy control plasmas. Significantly different cytokines and chemokines included IL-1 $\beta$  (reduced more than 2-fold ; p = 0.04; AUC = 0.71); TNF- $\alpha$  (elevated about 64%; p = 0.03; AUC = 0.76); and IP-10 (elevated about 50%; p = 0.04; AUC = 0.73). Nonetheless, while these differences were significant, they were relatively modest, and the AUC values calculated from the receiver operation condition (ROC) were also modest.

**[0080]** Measurement of cytokines and chemokines in PTSD plasma at 2 AM

**[0081]** Table 3 below shows measurements of cytokines and chemokines in plasma collected from both PTSD and healthy control patients at 2 AM. The table indicates that the two analytes, MCP-1 and MCP-4, still varied in opposite directions, and each was among the highest AUC values on the list. For the case of PTSD, the last row in Table 3 shows that the MCP-4/MCP-1 ratio was elevated 34% in plasma from PTSD patients compared to healthy controls. The P value, based on a two-tailed

t-test, was 0.02, and the ROC curve has an AUC of 0.75. The multiparameter analysis thus also identified the MCP-4/MCP-1 ratio as a candidate binary classifier for PTSD and healthy controls in both 9 AM and 2 AM plasma samples.

Table 3

Analyte	PTSD <sup>1</sup>	HC <sup>2</sup>	p-value <sup>3</sup>	Ratio <sup>4</sup>	AUC <sup>5</sup>
GM-CSF	0.39 ± 0.06	0.49 ± 0.09	0.50	≈ 0.81 ± 0.18	0.63
IFN-γ	1.01 ± 0.15	1.01 ± 0.15	0.98	≈ 1.09 ± 0.26	0.56
IL-10	2.45 ± 0.64	1.76 ± 0.56	0.22	≈ 1.40 ± 0.53	0.65
IL-12 p70	1.21 ± 0.37	0.67 ± 0.15	0.46	≈ 1.82 ± 0.66	0.53
IL-1β	0.16 ± 0.03	0.22 ± 0.04	0.14	≈ 1.33 ± 0.36	0.68
IL-2	0.31 ± 0.07	0.40 ± 0.06	0.11	≈ 1.39 ± 0.34	0.78
IL-6	1.33 ± 0.31	2.09 ± 0.63	0.17	≈ 1.32 ± 0.36	0.68
IL-8	2.63 ± 0.65	2.32 ± 0.41	0.84	≈ 1.05 ± 0.38	0.57
TNF-α	4.28 ± 0.32	3.91 ± 0.61	0.41	≈ 1.10 ± 0.21	0.55
Eotaxin	528.42 ± 68.32	520.89 ± 90.82	0.71	≈ 1.03 ± 0.21	0.52
Eotaxin-3	5.34 ± 0.75	6.61 ± 1.01	0.25	≈ 0.84 ± 0.17	0.61
IP-10	287.92 ± 49.92	197.54 ± 37.57	0.97	≈ 1.48 ± 0.36	0.70
MCP-1	292.69 ± 33.33	333.08 ± 49.15	0.47	≈ 0.88 ± 0.16	0.67
MCP-4	375.52 ± 48.01	320.24 ± 59.16	0.22	≈ 1.17 ± 0.23	0.65
MDC	3807.36 ± 556.11	2962.75 ± 470.42	0.24	≈ 1.30 ± 0.39	0.61
MIP-1β	78.53 ± 10.84	93.43 ± 15.21	0.34	≈ 0.84 ± 0.17	0.61
TARC	87.96 ± 14.02	108.58 ± 19.72	0.38	≈ 0.81 ± 0.19	0.59
MCP1/MCP4	0.74 ± 0.09	1.02 ± 0.15	0.02	≈ 1.38 ± 0.26	0.74
MCP4/MCP1	1.20 ± 0.15	0.90 ± 0.14	0.02	≈ 1.34 ± 0.26	0.75

<sup>1</sup> average ± sem, pg/ml

<sup>2</sup> two-tailed t-test

<sup>3</sup> ↑ PTSD>HC; ↓ PTSD<HC

<sup>4</sup> Area Under the Curve of the ROC Curve

<sup>5</sup> ~LOD: (viz, the analyte was too low in either the plasma or the CSF to calculate accurately)

n.a.: not available.

**[0082]** Table 4 shows measurements of cytokines and chemokines in CSF, which were collected from both PTSD and healthy control patients at the 9 AM time point. Of the complete set of analytes, only reduction of IL-8 was able to approach significance in PTSD CSF. While IL-8 in PTSD CSF was reduced by about 25%, the p value (two tailed) was 0.06. Surprisingly, the MCP-4 and MCP-1 levels in the 9 AM CSF samples were the reverse of those found in plasma, and independent of PTSD. Specifically, in healthy control CSF, the MCP-1 levels were about 7-fold higher than in plasma, while the MCP-4 levels were about 100-fold lower. Furthermore, the MCP-4/MCP-1 ratio in CSF did

not significantly discriminate between PTSD and healthy control patients, as it does in the 2 AM or 9 AM plasma samples.

Table 4

Analyte	PTSD <sup>1</sup>	HC <sup>1</sup>	p-value <sup>2</sup>	Ratio <sup>3</sup>	AUC <sup>4</sup>
GM-CSF	~LLOD	~LLOD	n.a.	n.a.	n.a.
IFN- $\gamma$	~LLOD	~LLOD	n.a.	n.a.	n.a.
IL-10	0.79 ± 0.24	0.69 ± 0.32	0.21	~1.15 ± 0.68	0.69
IL-12 p70	~LLOD	~LLOD	n.a.	n.a.	n.a.
IL-1 $\beta$	0.08 ± 0.02	0.18 ± 0.04	0.04	~2.12 ± 0.63	0.71
IL-2	0.15 ± 0.04	0.17 ± 0.03	0.72	~0.83 ± 0.38	0.58
IL-4	0.47 ± 0.04	0.77 ± 0.16	0.15	~1.62 ± 0.33	0.74
IL-8	1.67 ± 0.56	1.98 ± 0.59	0.87	~0.84 ± 0.37	0.53
TNF- $\alpha$	2.57 ± 0.41	1.57 ± 0.33	0.03	~1.64 ± 0.34	0.76
Eotaxin	303.45 ± 37.95	496.61 ± 37.29	0.91	~1.61 ± 0.31	0.52
Eotaxin-3	6.90 ± 0.58	6.42 ± 0.38	0.58	~1.07 ± 0.19	0.63
IP-10	226.06 ± 30.53	149.66 ± 13.37	0.04	~1.51 ± 0.24	0.73
MCP-1	171.11 ± 17.01	207.16 ± 17.49	0.14	~0.83 ± 0.31	0.82
MCP-4	298.33 ± 27.80	208.62 ± 23.94	0.01	~1.43 ± 0.28	0.77
MDC	1850.02 ± 155.12	1680.60 ± 167.21	0.40	~1.08 ± 0.14	0.61
MIP-1 $\beta$	63.85 ± 8.12	55.38 ± 4.77	0.38	~1.18 ± 0.37	0.66
TARC	65.52 ± 13.86	67.32 ± 10.24	0.30	~1.27 ± 0.28	0.76
MCP1/MCP4	0.61 ± 0.06	1.12 ± 0.18	4E-03	~1.84 ± 0.33	0.84
MCP4/MCP1	1.82 ± 0.19	1.10 ± 0.36	4E-03	~1.66 ± 0.28	0.88

<sup>1</sup> average ± sem, pg/ml

<sup>2</sup> two-tailed t-test

<sup>3</sup> ↑ PTSD>HC; ↓ PTSD<HC

<sup>4</sup> Area Under the Curve of the ROC Curve

~LLOD: (viz, the analyte was too low in either the plasma or the CSF to calculate accurately)  
n.a.: not available

**[0083]** Figure 1 shows the dot-plot distributions of MCP-1 (Figure 1: a, b and c), MCP-4 (Figure 1: c, d and e) and the MCP-4/MCP-1 ratio (Figure 1: f, g and h) in PTSD and healthy control plasma at 2 AM and 9 AM, and in CSF at 9 AM, respectively. The MCP-1 levels in the 2 AM (Figure 1a) and the 9 AM (Figure 1b) plasma samples trend lower than levels for the healthy controls.

**[0084]** In contrast, in the 9 AM CSF (Figure 1c), the MCP-1 levels were similar for both PTSD and healthy controls, and were about 7 fold greater than MCP-1 levels in the parallel 9 AM plasma samples. On the other hand, Figure 1d (plasma 2 AM) and Figure 1e (plasma 9 AM) show that MCP-4 was elevated in PTSD plasma. However, levels of MCP-4 were similar in both PTSD and healthy controls in 9 AM CSF (Figure 1f), and contained about 100-fold less MCP-4 than in parallel 9 AM

plasma from either cohort. The MCP-4/MCP-1 ratio at 2 AM (Figure 1g) and 9 AM (Figure 1h) were elevated in PTSD plasma, but was low in the 9 AM CSF (Figure 1i).

**[0085]** Figure 4 also shows a difference plot for  $([\text{MCP-4}] - [\text{MCP-1}])$  from the 9 AM plasma samples. The statistical significance for the difference was the same as for the ratio ( $p = 0.004$ ).

**[0086]** Figure 2a shows the 24 hour profile for the MCP-4/MCP-1 ratio in plasma from 5 PTSD and 5 healthy controls. The data indicate that across the entire 24 hour time period, the scale-free MCP-4/MCP-1 ratio for PTSD patients remained approximately twice that of healthy controls. Thus the ratio itself constitutes a viable metric that can be computed at any time a blood collection is made. Normalized and filtered data in Figure 2b shows that the MCP4/MCP-1 ratio in healthy controls peaks once in the late night hours. The PTSD patients, on the other hand, have a two peaks, coinciding with the late night healthy control peak, and another occurring later in the morning.

**[0087]** Figure 2c also shows that MCP-4 peaks four times throughout the day in PTSD patients, compared to only once in healthy controls. Furthermore, the late night MCP-4 peak in PTSD patients trails the peak times healthy control by almost three hours. Similar but unique temporal disorder appears to also characterize the MCP-1 profile. For example, Figure 2d shows that there is a late night peak in MCP-1 concentration in PTSD patients and healthy controls, but the late night peak in PTSD patients trails by nearly six hours.

**[0088]** To further verify the specificity and significance of the MCP-4 and MCP-1 signals for PTSD, the circadian pattern of expression of seven other chemokines was tested for significance between PTSD patients and healthy controls across the entire 24 hour time period. Although there was an average difference between PTSD and healthy controls for some of these analytes, the variance among patients, shows substantial overlap in levels in all chemokines tested except for MCP-4. Figure 3 plots the p-values for the hourly differences between PTSD and healthy controls for all chemokines tested, versus the MCP-4/MCP-1 ratio, across the circadian 24 hour time period. The P-values for, MCP-4 and the MCP-4/MCP-1 ratio are in the range of between  $p = 0.01$  to  $0.0001$ . The best statistics for the MCP-4/MCP-1 ratio are at 3-4 hours past Z=0 (8-10 AM). In contrast to MCP-4, the other analytes were clustered individually in the statistical space occupied by p values between 0.1 and 1.0.

**[0089]** However, the noisy properties of individual circadian rhythm components is well known in the chronobiology literature. An alternative solution has been to compare differences in circadian rhythm for specific analytes by (i) filtering (“smoothing out”) the variation from hour to hour by making a moving average of every three hours; (ii) averaging the results for 5 individuals; (iii) and

ratio'ing all data to the mean for the entire 24 hour period [28]. Using these methods, Figure 7(A-H) shows that for the different chemokines tested, the circadian rhythms are disordered for PTSD patients, although significant, quantitative, time-independent differences can only be detected for the MCP-4/MCP-1 ratio. It is indeed not typical that a ratio of two unrelated markers would be useful for identifying a subject having a specific disease or condition.

**[0090]** Figure 8A shows the differences between average log plasma MCP-4/MCP-1 ratio in female PTSD patients vs female healthy controls. PTSD females are greater than healthy control females at every hour and the differences are significant, or trend to being significant at each hour ( $p < 0.05$ ), across circadian time. Figure 8B shows the differences between average log plasma MCP-4/MCP-1 ratio in male PTSD patients vs male healthy controls. PTSD males are significantly greater than Healthy Control males at every hour ( $p < 0.05$ ). Figure 8C shows the differences between average log plasma MCP-4/MCP-1 ratio in all PTSD patients vs all healthy controls. All PTSD patients are greater than all Healthy Controls at every hour and the differences are significant ( $p < 0.05$ ). P values for each of the differences (Figure 8A-8C) at each hour are shown in Figure 8D. Error bars are +/- SEM (standard error of the mean).

**[0091]** Figure 9A shows the differences between average log plasma MIP-1 $\beta$  levels in female PTSD patients vs female healthy controls. PTSD Females are greater than Healthy Control females at every hour and the differences are significant, or trend to being significant at each hour across circadian time. ( $p < 0.05$ ). Figure 9B shows the differences between average log plasma MIP-1 $\beta$  levels in male PTSD patients vs male healthy controls. PTSD males are trend slightly greater than Healthy Control males at every hour, but these differences at every hour are not significant across circadian time, ( $p < 0.05$ ). Figure 9C shows the differences between average log plasma MIP-1 $\beta$  levels in all PTSD patients vs all healthy controls. All PTSD patients trend greater than all Healthy Controls at every hour. However, this trend is based on the contribution from female PTSD patients only. Figure 9D shows the significance of log plasma concentration differences for MIP-1 $\beta$  over circadian time. Red horizontal line is the same as  $P = 0.05$  on a arithmetic scale. Male PTSD (dotted black line); female PTSD (dashed black line); all PTSD (solid black line). Vertical axis is log P value. Error bars are +/- SEM (standard error of the mean). P values for the difference at each hour are shown in Figure 9D.

**[0092]** Figure 10A shows the differences between average log plasma TARC levels in female PTSD patients vs female healthy controls. Differences between PTSD females and healthy control females at every hour are not significant ( $p < 0.05$ ). Figure 10B shows the differences between average log plasma TARC levels in male PTSD patients are lower than male healthy controls. PTSD males are differ significantly at each hour across circadian time from healthy controls only at about Z -12 and

Z, ( $p < 0.05$ ). Figure 10C shows the differences between average log plasma TARC levels in all PTSD patients vs all healthy controls. There are no significant differences at each hour across circadian time, ( $p < 0.05$ ). Figure 10D shows the significance of log plasma concentration differences for TARC over circadian time. Red horizontal line is the same as  $P = 0.05$  on an arithmetic scale. Male PTSD (dotted black line); female PTSD (dashed black line); all PTSD (solid black line). Male PTSD patients differ significantly from male healthy controls at every hour across circadian time only at about Z -12 and Z, ( $p < 0.05$ ). Error bars are +/- SEM (standard error of the mean). P values for the difference at each hour are shown in Figure 10D.

**[0093]** All references herein are incorporated by reference.

**[0094]** 1. Bonne O, Gill JM, Luckenbaugh DA, Collins C, Owens MJ, et al. (2011) Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. *J Clin Psychiatry* 72: 1124-1128.

**[0095]** 2. Association AP (2013) Diagnostic and Statistical Manual of Mental disorders. Washington DC: American Psychiatric Publishing.

**[0096]** 3. <http://www.behavenet.com/capsules/disorders/ptsd.htm>.

**[0097]** 4. Boscarino JA (2004) Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. *Ann N Y Acad Sci* 1032: 141-153.

**[0098]** 5. Gill JM, Saligan L, Woods S, Page G (2009) PTSD is associated with an excess of inflammatory immune activities. *Perspect Psychiatr Care* 45: 262-277.

**[0099]** 6. Pace TW, Heim CM (2011) A short review on the psychoneuroimmunology of posttraumatic stress disorder: from risk factors to medical comorbidities. *Brain Behav Immun* 25: 6-13.

**[00100]** 7. Daskalakis NP, Lehrner A, Yehuda R (2013) Endocrine aspects of post-traumatic stress disorder and implications for diagnosis and treatment. *Endocrinol Metab Clin North Am* 42: 503-513.

**[00101]** 8. Elenkov IJ, Iezzoni DG, Daly A, Harris AG, Chrousos GP (2005) Cytokine dysregulation, inflammation and well-being. *Neuroimmunomodulation* 12: 255-269.

**[00102]** 9. Cunningham-Bussel AC, Root JC, Butler T, Tuescher O, Pan H, et al. (2009) Diurnal cortisol amplitude and fronto-limbic activity in response to stressful stimuli. *Psychoneuroendocrinology* 34: 694-704.

**[00103]** 10. Raison CL, Miller AH (2003) When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. *Am J Psychiatry* 160: 1554-1565.

**[00104]** 11. Silverman MN, Pearce BD, Biron CA, Miller AH (2005) Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. *Viral Immunol* 18: 41-78.

**[00105]** 12. Spivak B, Shohat B, Mester R, Avraham S, Gil-Ad I, et al. (1997) Elevated levels of serum interleukin-1 beta in combat-related posttraumatic stress disorder. *Biol Psychiatry* 42: 345-348.

**[00106]** 13. von Kanel R, Hepp U, Kraemer B, Traber R, Keel M, et al. (2007) Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. *J Psychiatr Res* 41: 744-752.

**[00107]** 14. Maes M, Lin AH, Delmeire L, Van Gastel A, Kenis G, et al. (1999) Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. *Biol Psychiatry* 45: 833-839.

**[00108]** 15. Tucker P, Jeon-Slaughter H, Pfefferbaum B, Khan Q, Davis NJ (2010) Emotional and biological stress measures in Katrina survivors relocated to Oklahoma. *Am J Disaster Med* 5: 113-125.

**[00109]** 16. Baker DG, Ekhator NN, Kasckow JW, Hill KK, Zoumakis E, et al. (2001) Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. *Neuroimmunomodulation* 9: 209-217.

**[00110]** 17. Geraciotti TD, Jr., Baker DG, Ekhator NN, West SA, Hill KK, et al. (2001) CSF norepinephrine concentrations in posttraumatic stress disorder. *Am J Psychiatry* 158: 1227-1230.

**[00111]** 18. Hoge EA, Brandstetter K, Moshier S, Pollack MH, Wong KK, et al. (2009) Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. *Depress Anxiety* 26: 447-455.

**[00112]** 19. Baker DG, Nievergelt CM, O'Connor DT (2012) Biomarkers of PTSD: neuropeptides and immune signaling. *Neuropharmacology* 62: 663-673.

**[00113]** 20. Gill J, Luckenbaugh D, Charney D, Vythilingam M (2010) Sustained elevation of serum interleukin-6 and relative insensitivity to hydrocortisone differentiates posttraumatic stress disorder with and without depression. *Biol Psychiatry* 68: 999-1006.

**[00114]** 21. Ross RJ, Ball WA, Sullivan KA, Caroff SN (1989) Sleep disturbance as the hallmark of posttraumatic stress disorder. *Am J Psychiatry* 146: 697-707.

**[00115]** 22. Harvey AG, Jones C, Schmidt DA (2003) Sleep and posttraumatic stress disorder: a review. *Clin Psychol Rev* 23: 377-407.

**[00116]** 23. Pollard JR, Eidelman O, Mueller GP, Dalgard CL, Crino PB, et al. (2012) The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy. *Front Neurol* 3: 181.

**[00117]** 24. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S, et al. (2012) CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. *PLoS One* 7: e30525.

**[00118]** 25. Wild E, Magnusson A, Lahiri N, Krus U, Orth M, et al. (2011) Abnormal peripheral chemokine profile in Huntington's disease. *PLoS Curr* 3: Rrn1231.

**[00119]** 26. Janelidze S, Ventorp F, Erhardt S, Hansson O, Minthon L, et al. (2013) Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. *Psychoneuroendocrinology* 38: 853-862.

**[00120]** 27. Irwin DJ, McMillan CT, Toledo JB, Arnold SE, Shaw LM, et al. (2012) Comparison of cerebrospinal fluid levels of tau and Abeta 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. *Arch Neurol* 69: 1018-1025.

**[00121]** 28. Eckel-Mahan KL, Patel VR, de Mateo S, Orozco-Solis R, Ceglia NJ, et al. (2013) Reprogramming of the circadian clock by nutritional challenge. *Cell* 155: 1464-1478.

**[00122]** 29. Garcia-Zepeda EA, Combadiere C, Rothenberg ME, Sarafi MN, Lavigne F, et al. (1996) Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. *J Immunol* 157: 5613-5626.

**[00123]** 30. Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, et al. (1999) CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. *Blood* 94: 1899-1905.

**[00124]**31. Segman RH, Shefi N, Goltser-Dubner T, Friedman N, Kaminski N, et al. (2005) Peripheral blood mononuclear cell gene expression profiles identify emergent post-traumatic stress disorder among trauma survivors. *Mol Psychiatry* 10: 500-513, 425.

**[00125]**32. Yehuda R, Cai G, Golier JA, Sarapas C, Galea S, et al. (2009) Gene expression patterns associated with posttraumatic stress disorder following exposure to the World Trade Center attacks. *Biol Psychiatry* 66: 708-711.

**[00126]**33. Neylan TC, Sun B, Rempel H, Ross J, Lenoci M, et al. (2011) Suppressed monocyte gene expression profile in men versus women with PTSD. *Brain Behav Immun* 25: 524-531.

**[00127]**34. Nguyen KD, Fentress SJ, Qiu Y, Yun K, Cox JS, et al. (2013) Circadian gene Bmal1 regulates diurnal oscillations of Ly6C(hi) inflammatory monocytes. *Science* 341: 1483-1488.

**[00128]**35. Druzd D, Scheiermann C (2013) Immunology. Some monocytes got rhythm. *Science* 341: 1462-1464.

**[00129]**36. Born J, Lange T, Hansen K, Molle M, Fehm HL (1997) Effects of sleep and circadian rhythm on human circulating immune cells. *J Immunol* 158: 4454-4464.

**[00130]**37. Grimaldi B, Nakahata Y, Sahar S, Kaluzova M, Gauthier D, et al. (2007) Chromatin remodeling and circadian control: master regulator CLOCK is an enzyme. *Cold Spring Harb Symp Quant Biol* 72: 105-112.

**[00131]**38. Menet JS, Rosbash M (2011) When brain clocks lose track of time: cause or consequence of neuropsychiatric disorders. *Curr Opin Neurobiol* 21: 849-857.

**What is Claimed is:**

1. A method of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD), the method comprising
  - a) determining the ratio of monocyte chemoattractant protein 4 (MCP-4) to monocyte chemoattractant protein 1 (MCP-1) in at least one sample obtained from the subject, and
  - b) comparing the MCP-4/MCP-1 ratio (MMR) in the at least one sample to a normal MMR to determine if the subject's MMR is altered compared to the normal MMR, wherein a change in the subject's MMR is indicative that the subject has an increased risk of suffering from PTSD.
2. The method of claim 1, wherein the normal MMR comprises the subject's MMR prior to the onset of PTSD.
3. The method of claim 1, wherein the normal MMR comprises an MMR generated from a population of individuals that do not suffer from PTSD.
4. The method of any of claims 1-3, wherein the at least one sample is a plasma sample obtained from whole blood taken from the subject.
5. The method of claim 4, wherein the whole blood is taken from the subject at one or more time points.
6. The method of claim 5, wherein the whole blood is taken from the subject at about 2 am (0200) and/or at about 9 am (0900).
7. The method of any of claims 1-6, wherein the subject was diagnosed with a depressive disorder prior to determining the MMR is the at least one sample obtained from the subject.
8. The method of claim 7, wherein the subject is receiving treatment for the depressive disorder, prior to determining the MMR is the at least one sample obtained from the subject.

9. The method of claim 8, wherein the treatment for the depressive disorder comprises administering at least one selective serotonin reuptake inhibitor (SSRI) to the subject.
10. The method of claim 9, wherein the SSRI is selected from the group consisting of citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, sertraline and zimelidine.
11. The method of any of claims 1-6, wherein the subject has not been diagnosed with a depressive disorder.
12. A method of diagnosing post-traumatic stress disorder (PTSD) in a subject suspected of having PTSD, the method comprising
  - a) determining the ratio of monocyte chemoattractant protein 4 (MCP-4) to monocyte chemoattractant protein 1 (MCP-1) in a sample obtained from the subject, and
  - b) comparing the MCP-4/MCP-1 ratio (MMR) in the sample to a normal MMR to determine if the subject's MMR is altered compared to the normal MMR,  
wherein a change in the subject's MMR compared to those defined as having a normal MMR is indicative that the subject is suffering from PTSD.
13. The method of claim 12, wherein the normal MMR comprises the subject's MMR prior to the onset of PTSD.
14. The method of claim 12, wherein the normal MMR comprises an MMR generated from a population of individuals that do not suffer from PTSD.
15. The method of any of claims 12-14, wherein the at least one sample is a plasma sample obtained from whole blood taken from the subject.
16. The method of claim 15, wherein the whole blood is taken from the subject after midnight and before noon.
17. The method of claim 16, wherein the whole blood is taken from the subject at about 2 am (0200) and/or at about 9 am (0900).
18. The method of any of claims 12-17, wherein the subject was diagnosed with a depressive disorder prior to determining the MMR is the at least one sample obtained from the subject.

19. The method of claim 18, wherein the subject is receiving treatment for the depressive disorder, prior to determining the MMR is the at least one sample obtained from the subject.
20. The method of claim 19, wherein the treatment for the depressive disorder comprises administering at least one selective serotonin reuptake inhibitor (SSRI) to the subject.
21. The method of claim 20, wherein the SSRI is selected from the group consisting of citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, sertraline and zimelidine.
22. A method of monitoring the progression of post traumatic stress disorder (PTSD) in a subject, the method comprising
  - a) analyzing at least two samples from a subject with each sample taken on different days to determine the ratios of monocyte chemoattractant protein 4 (MCP-4) to monocyte chemoattractant protein 1 (MCP-1), and
  - b) comparing the MCP-4/MCP-1 ratios (MMRs) over time to determine if the subject's MMR is changing over time,

wherein an increase in the subject's MMR over time is indicative that the PTSD is progressing in the subject, and wherein a decrease or no change in the subject's MMR over time is indicative that the PTSD is not progressing in the subject.
23. The method of claim 22, wherein the at least two samples are plasma samples obtained from whole blood taken from the subject.
24. The method of claim 23, wherein the whole blood is taken from the subject after midnight and before noon each day on which the samples are obtained.
25. The method of claim 23, wherein the whole blood is taken from the subject at about 2 am (0200) and/or at about 9 am (0900) each day on which the samples are obtained.
26. The method of any of claims 22-25, wherein the subject was diagnosed with a depressive disorder prior to determining the MMR in the subject.
27. The method of claim 26, wherein the subject is receiving treatment for the depressive disorder, prior to determining the MMR in the subject.

28. The method of claim 27, wherein the treatment for the depressive disorder comprises administering at least one selective serotonin reuptake inhibitor (SSRI) to the subject.
29. The method of claim 28, wherein the SSRI is selected from the group consisting of citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, sertraline and zimelidine.
30. The method of any of claims 22-25, wherein the subject has not been diagnosed with a depressive disorder.
31. The method of any one of claims 22-30, wherein the subject is receiving treatment for the PTSD.
32. A method of treating a subject with post-traumatic stress disorder (PTSD), the method comprising
  - a) determining the ratio of monocyte chemoattractant protein 4 (MCP-4) to monocyte chemoattractant protein 1 (MCP-1) in a sample obtained from the subject, and
  - b) comparing the MCP-4/MCP-1 ratio (MMR) in the sample to a normal MMR to determine if the subject's MMR is altered compared to the normal MMR, wherein a change in the subject's MMR compared to those defined as having a normal MMR is indicative that the subject is suffering from PTSD, and
  - c) administering to the subject with PTSD a therapeutic regimen to treat the PTSD, wherein the therapeutic regimen is selected from the group consisting of cognitive behavioral therapy (CBT), administration of one or more selective serotonin reuptake inhibitors (SSRIs), administration of one or more anti-anxiety medications and administration of one or more anti-insomnia medications.
33. The method of claim 32, wherein the normal MMR comprises the subject's MMR prior to the onset of PTSD.
34. The method of claim 32, wherein the normal MMR comprises an MMR generated from a population of individuals that do not suffer from PTSD.
35. The method of any of claims 32-34, wherein the at least one sample is a plasma sample obtained from whole blood taken from the subject.

36. The method of claim 35, wherein the whole blood is taken from the subject after midnight and before noon.
37. The method of claim 36, wherein the whole blood is taken from the subject at about 2 am (0200) and/or at about 9 am (0900).
38. The method of claim 32, wherein the SSRI is selected from the group consisting of citalopram, dapoxetine, escitalopram, fluoxetine, fluvoxamine, indalpine, paroxetine, sertraline and zimelidine.
39. A method of determining if a male subject is at risk of developing post-traumatic stress disorder (PTSD), the method comprising
  - a) determining levels of at least one marker selected from the group consisting of monocyte chemoattractant protein 1 (MCP-1) and thymus and activation-regulated chemokine (TARC) in at least one sample obtained from a male subject, and
  - b) comparing the MCP-1 or TARC levels in the at least one sample to normal MCP-1 or TARC levels to determine if the male subject's MCP-1 or TARC levels are altered compared to the normal MCP-1 or TARC levels,

wherein a change in the male subject's MCP-1 or TARC levels indicative that the male subject has an increased risk of suffering from PTSD.
40. The method of claim 39, wherein the marker is MCP-1, and the change in the MCP-4 levels that is indicative that the male subject has an increased risk of suffering from PTSD is a decrease from normal levels.
41. The method of claim 39, wherein the marker is TARC, and the change in the TARC levels that is indicative that the male subject has an increased risk of suffering from PTSD is a decrease from normal levels.
42. The method of any of claims 39-41, wherein the at least one sample is a plasma sample obtained from whole blood taken from the subject.
43. A method of determining if a female subject is at risk of developing post-traumatic stress disorder (PTSD), the method comprising

- a) determining levels of at least one marker selected from the group consisting of monocyte chemoattractant protein 4 (MCP-4) and monocyte interacting protein 1 $\beta$  (MIP-1 $\beta$ ) in at least one sample obtained from a female subject, and
- b) comparing the MCP-4 or MIP-1 $\beta$  levels in the at least one sample to normal MCP-4 or MIP-1 $\beta$  levels to determine if the female subject's MCP-4 or MIP-1 $\beta$  levels are altered compared to the normal MCP-4 or MIP-1 $\beta$  levels,

wherein a change in the female subject's MCP-4 or MIP-1 $\beta$  levels indicative that the female subject has an increased risk of suffering from PTSD.

44. The method of claim 43, wherein the marker is MCP-4, and the change in the MCP-4 levels that is indicative that the female subject has an increased risk of suffering from PTSD is an increase over normal levels.










45. The method of claim 43, wherein the marker is MIP-1 $\beta$ , and the change in the MIP-1 $\beta$  levels that is indicative that the female subject has an increased risk of suffering from PTSD is an increase over normal levels.

46. The method of any of claims 43-45, wherein the at least one sample is a plasma sample obtained from whole blood taken from the subject.

47. A kit for detecting or diagnosing post-traumatic stress disorder (PTSD) comprising at least one set of antibodies that specifically bind to at least one of monocyte chemoattractant protein 4 (MCP-4), monocyte interacting protein 1 $\beta$  (MIP-1 $\beta$ ), monocyte chemoattractant protein 1 (MCP-1) or thymus and activation-regulated chemokine (TARC), wherein the antibodies are immobilized onto a solid surface.

48. The kit of claim 47, wherein the kit comprises four sets of antibodies, with each set being able to specifically bind to MCP-1, MCP-4, TARC and MIP-1 $\beta$ , respectively.

1/20



2/20




FIG. 2A

FIG. 2B




FIG. 2C

FIG. 2D

3/20

## SIGNIFICANCE OF DIFFERENCE BETWEEN CONTROLS AND PTSD PATIENTS








FIG. 3

4/20


**FIG. 4A****FIG. 4B**

5/20


**FIG. 5A**

**FIG. 5B**

7/20

**FIG. 5C**

8/20

**FIG. 5D**

9/20








FIG. 6



10/20

**FIG. 7A**



11/20

**FIG. 7B**



12/20

**FIG. 7C**



13/20

**FIG. 7D**



14/20

**FIG. 7E**

15/20


**FIG. 7F**

16/20


**FIG. 7G**

17/20


MCP4/MCP1




MCP4/MCP1

**FIG. 7H**


AVERAGE LOG MCP4/MCP1, FEMALES

**FIG. 8A**


AVERAGE LOG MCP4/MCP1, MALES







AVERAGE LOG MCP4/MCP1, BOTH GENDERS

**FIG. 8C**






LOG MCP4/MCP1: SIGNIFICANCE OF PTSD VS CONTROL

**FIG. 8B****FIG. 8D**

19/20



20/20

**FIG. 10A****FIG. 10C****FIG. 10B****FIG. 10D**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US16/55675

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - G01N 33/68; A61P 25/24; A61K 31/135, 31/138, 31/343 (2017.01)

CPC - G01N 33/6893, 33/6896; A61K 31/135, 31/138, 31/343

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: G01N 33/68; A61P 25/24; A61K 31/135, 31/138, 31/343 (2017.1); CPC: G01N 33/6893, 33/6896, 2333/00, 2333/47, 2333/52, 2333/435, 2333/521, 2333/4727, 2800/00, 2800/301; A61K 31/135, 31/138, 31/343

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatSeer (US, EP, WO, JP, DE, GB, CN, FR, KR, ES, AU, IN, CA, INPADOC Data); Google, Google Scholar, EBSCO, Terms: sample, collection, time, disease, diagnosis, blood, circadian, rhythm, PTSD, MCP-4, MCP-1, ratio, TARC, antibody, MIP-1beta, CCL13, CCL17, CCL2, CCL4, 9, 2, am, hour, chemokine, serum, draw, take, kit, tool, supply

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.**
X	(POLLARD, H.B.) Uncovering Novel Biomarkers for Early Diagnosis of PostTraumatic Stress Disorder (PTSD); Webpage [online]. 26 February 2014 [retrieved on 24 January 2017]; Retrieved from the Internet: <URL: http://cdmrp.army.mil/phtbi/research_highlights/15pollard_highlight>; 1st – 2nd paragraph	1, 3, 4/1, 4/3, 12, 14, 15/12, 15/14, 16/15/12, 17/16/15/12, and 17/16/1514
Y		2, 4/2, 5/4/1-3, 6/5/4/1-3, 13, 15/13, 16/15/13, 17/16/15/13, 22-25, 26/22-25, 27/26/22-25, 28/27/26/22-25, 29/28/27/26/22-25, 30/22-25, 32-34, 35/32-34, 36/35/32-34, 37/36/35/32-34, 38, 48
X	US 2014/0220019 A1 (ABBVIE, INC.) 7 August 2014; paragraphs [0105] [0352], [0423]-[0424]	47
Y		22-25, 26/22-25, 27/26/22-25, 28/27/26/22-25, 29/28/27/26/22-25, 30/22-25, 48

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family

Date of the actual completion of the international search  
21 February 2017 (21.02.2017)

Date of mailing of the international search report

09 MAR 2017

Name and mailing address of the ISA/US  
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450  
Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300  
PCT OSP: 571-272-7774

**INTERNATIONAL SEARCH REPORT**

International application No. ....

PCT/US16/55675

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.: 7-11, 18-21, and 31  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

\*\*\*Please see supplemental page-\*\*\*

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-6, 12-17, 22-30, 32-38, 47 and 48

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US16/55675

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2015/0259740 A1 (POLLARD, H) 17 September 2015; claim 7; Table 1; paragraphs paragraph [0003], [0015], [0047], [0078], [0102]	2, 4/2, 5/4/1-3, 6/5/4/1-3, 13, 15/13, 16/15/13, 17/16/15/13, 22-23, 25, 26/22-23, 26/25, 27/26/22-23, 27/26/25, 28/27/26/22-23, 28/27/26/25, 29/28/27/26/22-23, 29/28/27/26/25/32-34, 35/32-34, 38, 30/22-23, 30/25, 36/35/32-34, and 37/36/35/32-34
Y	(THERMOFISHER.COM) SAFETY DATA SHEET. Webpage [online]. 30 April 2014 [Retrieved on 25 January 2017]. Retrieved from the Internet: <URL: https://tools.thermofisher.com/content/sfs/msds/2015/RF8937_MTR-NARF_EN.pdf>; page 1, 1st paragraph	48
Y	(INVITROGEN.COM) TARC/CCL17 ABfinity™ Recombinant Rabbit Monoclonal Antibody – Purified. Webpage [online]. 10 January 2011 [Retrieved on 25 January 2017]. Retrieved from the Internet: <URL: https://tools.thermofisher.com/content/sfs/manuals/700655_rb_x_TARC_mab.pdf> page 1, 1st column	48
Y	(EBIOSCIENCE.COM) AntiHuman CCL4 (MIP1beta); Webpage [online]. 6 April 2015 [Retrieved on 25 January 2017]. Retrieved from the Internet: <URL: http://www.ebioscience.com/human-ccl4-antibody-apc-fl34z3l.htm>. page 1, 1st paragraph	48
P, X	WO 2016/057775 A1 (THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.) 14 April 2016; entire document	1-3, 4/1-3, 5/4/1-3, 6/5/4/1-3, 12-14, 15/12-14, 16/15/12-14, 17/16/15/12-13, 22-25, 26/22-25, 27/26/22-25, 28/27/26/22-25, 29/28/27/26/22-25, 30/22-25, 32-34, 35/32-34, 36/35/32-34, 37/36/35/32-34, 38, 47-48

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.

PCT/US16/55675

\*\*\*Continued from Box No. III: Observations where unity of invention is lacking\*\*\*

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, Claims 1-6, 12-17, 22-30, 32-38, 47 and 48 are directed toward methods comprising a) determining the ratio of monocyte chemoattractant protein 4 (MCP-4) to monocyte chemoattractant protein 1 (MCP-1) in a sample obtained from the subject, and b) comparing the MCP-4/MCP-1 ratio (MMR) in the sample; and a kit therefor.

Group II, Claims 39-42 are directed toward a method of determining if a male subject is at risk of developing post-traumatic stress disorder (PTSD), the method comprising a) determining levels of activation-regulated chemokine (TARC) in at least one sample obtained from a male subject.

Group III, Claims 43-46 are directed toward a method of determining if a female subject is at risk of developing post-traumatic stress disorder (PTSD), the method comprising a) determining levels of monocyte interacting protein 1B (MIP-1B) in at least one sample obtained from a female subject.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical features of Group I include MCP-4/MCP-1 ratio, not present in either of Groups II or III; the special technical features of Group II include TARC, not present in either of Groups I or III; the special technical features of Group III include MIP-1B, not present in either of Groups I or II.

Groups I-III share the technical features including: a method of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD), the method comprising a) determining levels of at least one marker in at least one sample obtained from the subject, and b) comparing the levels in the at least one sample to normal levels to determine if the subject's levels are altered compared to the normal levels, wherein a change in the subject's levels indicative that the subject has an increased risk of suffering from PTSD. Groups I and II share the technical features including: monocyte chemoattractant protein 1 (MCP-1). Groups I and III share the technical features including: monocyte chemoattractant protein 4 (MCP-4).

However, these shared technical features are previously disclosed by US 2015/0259740 A1 to Pollard et al. (hereinafter "Pollard'740") in view of the document 'Cytokine and Chemokine Profiling of Plasma and CSF Identifies the MCP-4/MCP-1 Ratio as a Novel Candidate Plasma Biomarker for Chronic Post-Traumatic Stress Disorder' by Pollard et al. (hereinafter "Pollard'2013").

Pollard'740 discloses a method of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD) (a method of determining if a subject is at risk of developing post-traumatic stress disorder (PTSD); paragraph [0020]), the method comprising a) determining levels of at least one marker in at least one sample obtained from the subject (the method comprising a) determining levels of at least one marker in at least one sample obtained from the subject; paragraph [0020]), and b) comparing the levels in the at least one sample to normal levels (comparing the levels in the at least one sample to normal levels; paragraph [0020]) to determine if the subject's levels are altered compared to the normal levels (to determine if the subject's levels are altered compared to the normal levels; paragraph [0020]), wherein a change in the subject's levels indicative that the subject has an increased risk of suffering from PTSD (wherein a change in the subject's levels indicative that the subject has an increased risk of suffering from PTSD; paragraph [0020]).

Pollard'740 does not disclose MCP-1 or MCP-4.

Pollard'2013 discloses wherein the ratio of MCP4/MCP1 in a sample from a subject significantly discriminates between PTSD and normal controls (wherein the ratio of MCP4/MCP1 in a sample from a subject significantly discriminates between PTSD and normal controls; page S262, first column, second paragraph).

It would have been obvious to a person of ordinary skill in the art at the time of the invention was made to have modified the disclosure of Pollard'740 to have included the markers MCP-1 and MCP-4, and the ratio thereof, as disclosed by Pollard'2013, in order to better enable the determination of the presence and/or severity of PTSD in a patient with chronic PTSD.

Since none of the special technical features of the Groups I-III inventions is found in more than one of the inventions, and since all of the shared technical features are previously disclosed by a combination of the Pollard'740 and Pollard'2013 references, unity of invention is lacking.